MX2009004516A - Metodos y terapias de combinacion para tratar enfermedad de alzheimer. - Google Patents

Metodos y terapias de combinacion para tratar enfermedad de alzheimer.

Info

Publication number
MX2009004516A
MX2009004516A MX2009004516A MX2009004516A MX2009004516A MX 2009004516 A MX2009004516 A MX 2009004516A MX 2009004516 A MX2009004516 A MX 2009004516A MX 2009004516 A MX2009004516 A MX 2009004516A MX 2009004516 A MX2009004516 A MX 2009004516A
Authority
MX
Mexico
Prior art keywords
disease
combination therapies
methods
treating alzheimer
alzheimer
Prior art date
Application number
MX2009004516A
Other languages
English (en)
Inventor
David T Hung
Andrew Asher Protter
Original Assignee
Medivation Neurology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Neurology Inc filed Critical Medivation Neurology Inc
Publication of MX2009004516A publication Critical patent/MX2009004516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos y terapias de combinación para tratar y/o prevenir y/o disminuir el inicio y/o desarrollo de la enfermedad de Alzheimer usando pirido(4,3-b)indol hidrogenado (por ejemplo, dimebon) en conjunto con otro compuesto, sal farmacéuticamente aceptable o terapia para la enfermedad de Alzheimer.
MX2009004516A 2006-10-27 2007-10-26 Metodos y terapias de combinacion para tratar enfermedad de alzheimer. MX2009004516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85486606P 2006-10-27 2006-10-27
PCT/US2007/022645 WO2008051599A2 (en) 2006-10-27 2007-10-26 Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil

Publications (1)

Publication Number Publication Date
MX2009004516A true MX2009004516A (es) 2009-08-12

Family

ID=39315586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004516A MX2009004516A (es) 2006-10-27 2007-10-26 Metodos y terapias de combinacion para tratar enfermedad de alzheimer.

Country Status (15)

Country Link
US (1) US20100152108A1 (es)
EP (2) EP2086538B1 (es)
JP (1) JP2010507672A (es)
KR (1) KR20090087009A (es)
CN (1) CN101631547A (es)
AT (1) ATE549021T1 (es)
AU (1) AU2007309390A1 (es)
BR (1) BRPI0718437A2 (es)
CA (1) CA2667553A1 (es)
IL (2) IL198405A0 (es)
MX (1) MX2009004516A (es)
NO (1) NO20092051L (es)
RU (1) RU2009120048A (es)
SG (1) SG178000A1 (es)
WO (1) WO2008051599A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
UA98324C2 (ru) * 2007-04-05 2012-05-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20090221627A1 (en) 2007-09-20 2009-09-03 Alexey Aksinenko Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
WO2009120720A1 (en) 2008-03-24 2009-10-01 Medivation Technologies,Inc. Bridged heterocyclic compounds and methods of use
WO2010031054A1 (en) * 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
EP2344505A2 (en) 2008-09-29 2011-07-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
TWI482773B (zh) 2008-10-31 2015-05-01 Medivation Technologies Inc 氮呯并〔４，５－ｂ〕吲哚及使用方法
AU2009308706C1 (en) * 2008-10-31 2016-01-21 Medivation Technologies, Inc. Pyrido (4,3-b) indoles containing rigid moieties
US20100125085A1 (en) * 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyridoindole modulators of nmda receptor and acetylcholinesterase
WO2010075635A1 (en) * 2008-12-30 2010-07-08 Ramot At Tel Aviv University Ltd. Combination therapies using nap
KR20110132564A (ko) 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
WO2010115342A1 (zh) * 2009-04-10 2010-10-14 中国人民解放军军事医学科学院毒物药物研究所 含有四氢吡啶[4，3-b]吲哚衍生物的缓释组合物及该衍生物的制备方法
CN102480955B (zh) * 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
CA2760516A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
WO2011031816A2 (en) * 2009-09-11 2011-03-17 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN102711468B (zh) 2009-09-23 2014-07-09 梅迪维新技术公司 吡啶并[4，3-b]吲哚化合物及其使用方法
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
CA2775216A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
TR201001117A1 (tr) * 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2012016708A1 (en) * 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
AU2011305462B2 (en) 2010-09-23 2015-11-26 Abbvie Bahamas Ltd. Monohydrate of an azaadamantane derivative
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
JP2014505737A (ja) 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
WO2012122405A2 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Screening assays using stem cells and stem cell-derived neurons from mouse models of alzheimer's disease
DE102012003065A1 (de) * 2012-02-13 2013-08-14 Friedrich-Schiller-Universität Jena Neue bivalente Gammacarbolinderivate sowie deren Herstellung und Verwendung als Antidementiva
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
EP2866894A4 (en) * 2012-06-27 2016-03-16 Univ Miami COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
RU2496465C1 (ru) * 2012-11-15 2013-10-27 Борис Николаевич Анисимов Способ профилактики развития и прогрессирования болезни альцгеймера на курортном этапе
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016179217A1 (en) * 2015-05-06 2016-11-10 Ohio University Metal ion chelation for enhancing the effect of tissue plasminogen activator (tpa) in thromobolysis
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
CA3139082A1 (en) * 2019-05-21 2020-11-26 LA PharmaTech Inc. Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8204M (es) 1967-12-08 1970-09-14
DE1952800C3 (de) 1969-10-20 1974-04-18 Nautschno-Issledowatelskij Institut Farmakologii I Chimioterapii, Moskau 3,6-Dimethyl-l,2,3,4,4a,9a-hexahydro-gamma-carbolin-dihydrochlorid
US3718657A (en) 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
DE69822218T2 (de) 1997-12-05 2005-02-03 Eisai Co., Ltd. Donepezil polykristalle und verfharen zu ihrer herstellung
WO2000059544A1 (fr) 1999-03-31 2000-10-12 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
GEP20094759B (en) * 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CN1805737A (zh) * 2003-06-16 2006-07-19 欧乐根公司 美金刚胺(memantine)口服剂型
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches

Also Published As

Publication number Publication date
US20100152108A1 (en) 2010-06-17
KR20090087009A (ko) 2009-08-14
SG178000A1 (en) 2012-02-28
RU2009120048A (ru) 2010-12-10
WO2008051599A2 (en) 2008-05-02
IL219709A0 (en) 2012-06-28
EP2420235A1 (en) 2012-02-22
WO2008051599A3 (en) 2008-07-24
IL198405A0 (en) 2010-02-17
CN101631547A (zh) 2010-01-20
BRPI0718437A2 (pt) 2013-11-19
ATE549021T1 (de) 2012-03-15
AU2007309390A1 (en) 2008-05-02
EP2086538B1 (en) 2012-03-14
JP2010507672A (ja) 2010-03-11
NO20092051L (no) 2009-07-22
EP2086538A2 (en) 2009-08-12
CA2667553A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
MX2009004516A (es) Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
TW200722083A (en) Combinations and methods of using an indolinone compound
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
MX2020008616A (es) Rocio de fentanilo sublingual.
WO2010065751A3 (en) Formulations of guanylate cyclase c agonists and methods of use
GB2442915B (en) Perylenequinone derivatives and uses thereof
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
WO2007061737A3 (en) FUSED BICYCLIC mTOR INHIBITORS
WO2007025005A3 (en) Sustained release formulations of nalbuphine
TW200718689A (en) 2-Amino-quinazolin-5-ones
EP1720576A4 (en) PHOTODYNAMIC THERAPY FOR ACNE TREATMENT
EP1861161A4 (en) APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
HK1118550A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
IL179630A0 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
SI1899334T1 (sl) Naftiridinske spojine
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
GB0416508D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal